This company flits about the world, trying to raise capital, but also has to run away from its reputation. Because delivery is not in their DNA. In a small country like Israel, Yacov’s reputation would be inescapable. A fogey with an ugly old product and a stale story that keeps going back to Lifewatch, the company smart enough to ditch him. They like to file paperwork in different jurisdictions, but they don’t produce units in any volume and I bet they look after customers as well as they look are shareholders. Does anyone think it was necessary to delist from ASX to raise a paltry $15M and sell a convertible note for $5M? They change jurisdictions to avoid questions. They need to keep presenting themselves as new to investors, as if that’s why the product is unknown and unpopular. As if they’re a challenger — when really they’ve been around since 2014 — a year before the first Apple Watch — and have been rightly overlooked and overtaken. Australian GP’s weren’t sold. Numerous underwriters weren’t sold. Patients want the industry standard. Or the game changer. Yacov and his band of yes-men, fossils, and the capital-raising dentist are rightly shunned in any country unfortunate enough to deal with them. That’s why they need to pay Guthy Renker to sell their junk. Because their own brand is steaming doggy doo.
GMV Price at posting:
3.9¢ Sentiment: None Disclosure: Held